877149-83-2Relevant articles and documents
Ametoctradin is a Potent Qo Site Inhibitor of the Mitochondrial Respiration Complex III
Zhu, Xiaolei,Zhang, Mengmeng,Liu, Jingjing,Ge, Jingming,Yang, Guangfu
, p. 3377 - 3386 (2015/04/14)
Ametoctradin is a new Oomycete-specific fungicide under development by BASF. It is a potent inhibitor of the bc1 complex in mitochondrial respiration. However, its detailed action mechanism remains unknown. In the present work, the binding mode of ametoctradin was first uncovered by integrating molecular docking, MD simulations, and MM/PBSA calculations, which showed that ametoctradin should be a Qo site inhibitor of bc1 complex. Subsequently, a series of new 1,2,4-triazolo[1,5-a]pyrimidine derivatives were designed and synthesized to further understand the substituent effects on the 5- and 6-position of 1,2,4-triazolo[1,5-a]pyrimidine. The calculated binding free energies (ΔGcal) of newly synthesized analogues as Qo site inhibitors correlated very well (R2 = 0.96) with their experimental binding free energies (ΔGexp). Two compounds (4a and 4c) with higher inhibitory activity against porcine SQR than ametoctradin were successfully identified. The structural and mechanistic insights obtained from the present study will provide a valuable clue for future designing of a new promising bc1 inhibitor.
PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS KINASE JAK-2 INHIBITORS
-
, (2015/09/22)
A compound of the general formula (I), useful for treating myeloproliferative, cancer,or inflammatory diseases, wherein Q represents a six-membered heteroaromatic ring containing 2 N atoms and R1 is hydrogen atom,or Q represents a five-membered heteroaromatic ring containing 1 or 2 heteroatoms selected from the group consisting of N and S,one substituent R1 is attached at C or N atom of said Q ringand R1 is selected from the group consisting of C1-C4-alkyl and C3-C4-cycloalkyl;R2 represents-NR7aR7bor-CH2-NR8aR8b;R3 represents C1-C4-alkyl;R4 represents phenylora 5-or 6-membered heteroarylcontaining 1 or 2 heteroatoms selected from the group consisting of N and S, and R4 is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of halogen, trifluoromethyl,hydroxyl and C1-C4-alkoxyl;R5 and R6 independently represent hydrogenatom or C1-C4-alkyl,and at least one of R5 and R6 represents hydrogen atom;and other substituents are as defined in the specification; and pharmaceutically acceptable salts thereof.
PYRIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
-
Page/Page column 129, (2011/07/09)
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related conditions in both men and women, as well as a mammal in general (also referred to herein as a "subject"). For example, such conditions include endometriosis, uterine fibroids, polycystic ovarian disease, heavy menstrual bleeding, particularly menorrahagia and dysmenorrehea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to pyridinone derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
Monoalkylation of acetonitrile by primary alcohols catalyzed by iridium complexes
Anxionnat, Bruno,Gomez Pardo, Domingo,Ricci, Gino,Cossy, Janine
supporting information; experimental part, p. 4084 - 4087 (2011/09/21)
The monoalkylation of acetonitrile by primary alcohols was achieved in a one-pot sequence in the presence of iridium catalysts. A diversity of nitriles has been obtained from aryl- and alkyl-methanols in excellent yield.
SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS
-
Page/Page column 38; 39, (2008/12/04)
Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.
THERAPEUTIC FLUOROETHYLCYANO GUANIDINES
-
Page/Page column 19, (2008/12/04)
Disclosed herein is compound having a formula as described herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
